The Implantable Systems Performance Registry (ISPR) was developed to evaluate the long-term reliability and performance of market-released Medtronic Neuromodulation infusion and stimulation products. Completion Notice: The ISPR was created by Medtronic to monitor the performance of commercially available products. This registry was initially designed to track performance of Medtronic's implantable infusion and spinal cord stimulation systems beginning in August 2003 and June 2004, respectively. Medtronic DBS Systems were added to the ISPR in June 2009, and Sacral Neuromodulation Systems in April 2010. Medtronic retired the ISPR in April 2016 and merged the data collected from this registry into the Product Surveillance Registry (PSR). Please refer to that record, Clinical Trials identifier: NCT01524276, for further information.
Study Type
OBSERVATIONAL
Enrollment
10,981
Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
Unnamed facility
Huntsville, Alabama, United States
Unnamed facility
Scottsdale, Arizona, United States
Unnamed facility
Aliso Viejo, California, United States
Unnamed facility
Los Angeles, California, United States
Unnamed facility
Napa, California, United States
Unnamed facility
Product Performance
To quantify and compare the rates of device-related events for market-released Medtronic Neuromodulation infusion and stimulation devices
Time frame: Annually
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Palm Springs, California, United States
Unnamed facility
Pasadena, California, United States
Unnamed facility
San Diego, California, United States
Unnamed facility
Upland, California, United States
Unnamed facility
Washington D.C., District of Columbia, United States
...and 40 more locations